Skip to content
Trial Eligibility
Menu

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

NCT07002034

This study is recruiting at 32 US sites in 25 states, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Adjustment Disorder

Eligibility basics and study details

Study type
Interventional
Phase
Phase 2
Ages
18 to 80 years
Sex
All
Healthy volunteers
Not accepted
Sponsor
Reunion Neuroscience Inc
Last updated on ClinicalTrials.gov
September 15, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Alabama · 1

  • UAB, Psychiatry and Behavioral Neurology · Birmingham, AL

Arizona · 1

  • University of Arizona · Tucson, AZ

California · 2

  • Kadima Neuropsychiatry Institute · San Diego, CA
  • Providence Medical Foundation · Santa Rosa, CA

Colorado · 1

  • University of Colorado · Aurora, CO

Florida · 1

  • University of South Florida, Department of Psychiatry and Behavioral Neuroscience · Tampa, FL

Georgia · 1

  • Emory University · Atlanta, GA

Hawaii · 1

  • Hawaii Pacific Neuroscience · Honolulu, HI

Illinois · 2

  • Rush University Medical Center · Chicago, IL
  • University of Chicago Medical Center · Chicago, IL

Kansas · 1

  • The University of Kansas Medical Center · Kansas City, KS

Louisiana · 1

  • LSU Health Shreveport · Shreveport, LA

Maryland · 2

  • Sunstone Therapies, PC · Rockville, MD
  • Sheppard Pratt · Towson, MD

Massachusetts · 2

  • Dana Farber Cancer Institute · Boston, MA
  • University of Massachusetts Chan Medical Center · Worcester, MA

Michigan · 2

  • University of Michigan · Ann Arbor, MI
  • Henry Ford Health · Novi, MI

Nebraska · 1

  • University of Nebraska Medical Center · Omaha, NE

New Mexico · 1

  • University of New Mexico, School of Medicine · Albuquerque, NM

New York · 2

  • Roswell Park Center Institute · Buffalo, NY
  • NYU Langone Health · New York, NY

North Carolina · 1

  • University of North Carolina at Chapel Hill · Chapel Hill, NC

Ohio · 2

  • Cleveland Clinic · Cleveland, OH
  • The Ohio State University, Department of Psychiatry · Columbus, OH

Pennsylvania · 1

  • University of Pennsylvania · Philadelphia, PA

Tennessee · 1

  • Alliance for Multispecialty Research Clinical · Knoxville, TN

Texas · 1

  • Dell Medical School, University of Texas at Austin · Austin, TX

Utah · 1

  • Cedar Clinical Research Inc. · Draper, UT

Virginia · 1

  • UVA Center for Psychiatric Clinical Research · Charlottesville, VA

Washington · 1

  • Seattle Neuropsychiatric Treatment Center · Seattle, WA

Wisconsin · 1

  • University of Wisconsin at Madison · Madison, WI

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.